Innovative Technology Development for Cancer Research (R21)

The summary for the Innovative Technology Development for Cancer Research (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Innovative Technology Development for Cancer Research (R21): Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing technically innovative feasibility studies focused on early stage development of cancer-relevant technologies. If successful, these technologies would accelerate the research and understanding of basic cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R21 applications and is suitable for projects at their inception, conceptual or idea based, where technical feasibility of the proposed technology or methodology has not yet been established. The R21 mechanism requires high potential impact and allows for an element of technical risk; projects proposed in response to this FOA may reflect this level of risk but must have concurrent potential to produce a major impact in a broad area of cancer-relevant research. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished). Projects proposing to use technology that is already established or projects where the novelty resides in the biological or clinical question being pursued are examples of topics not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $5,000,000 to this FOA in fiscal year 2010 to fund up to 15 applications in response to this FOA.

Federal Grant Title:	Innovative Technology Development for Cancer Research (R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-10-005
Type of Funding:	Grant
CFDA Numbers:	93.393
CFDA Descriptions:	Cancer Cause and Prevention Research
Current Application Deadline:	Sep 30, 2010
Original Application Deadline:	Sep 30, 2010
Posted Date:	Oct 26, 2009
Creation Date:	Oct 26, 2009
Archive Date:	Oct 31, 2010
Total Program Funding:	$500,000
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed); • Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional); • Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinica...; • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...; • Advanced Development of Informatics Technologies for Cancer Research and Management (U24 C...; • Pilot Studies in Pancreatic Cancer; • Cancer Prevention Research Small Grant Program; • Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health: • NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices ...; • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...; • Immune Tolerance Network (UM1 Clinical Trial Required); • Coordinating Center for National Resource Network for the Study of Human Auditory and Vest...; • National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Cl...